Fig. 3

Treatment exposure and responses are illustrated in individual patients based on RANO criteria. Only patients who had ≥1 evaluable postbaseline tumor assessment are included (n = 8). A Treatment and response duration, including confirmed and unconfirmed responses, are illustrated. B Tumor volume compared to baseline when patients achieve best efficacy during treatment. C Longitudinal percentage change from baseline in tumor size are illustrated. D Survival estimates are illustrated in patients who received ≥1 dose of Sintilimab, Bevacizumab, and Temozolomide including progression-free survival (PFS) based on RANO criteria